… Ltd., a privately held biotechnology company based in the … million. The transaction strengthens Amgen’s oncology research pipeline … . Through the acquisition, Amgen gains an investigational small … . Following the transaction, Amgen plans to integrate Dark …

… treatments. US multinational biotechnology company Amgen has announced the … part of the acquisition, Amgen will integrate Dark Blue … research and development at Amgen, said: “Acute myeloid … Blue Therapeutics, added: “Amgen has the expertise, resources …

… Dark Blue Therapeutics by US biotechnology company Amgen Inc. has produced a … welcomed the transaction. “Evotec welcomes Amgen’s acquisition of Dark Blue … we see the acquisition by Amgen as strong confirmation of Dark …

… of Business Performance at Amgen and has more than … scale change initiatives in the biotechnology industry. She has also … WEV’s corporate partnership with Amgen, supporting alignment between corporate … as a corporate leader with Amgen, comes at an especially …

… acquired Dark Blue Therapeutics, a biotechnology company located in the United … of specific tumor targets.” References Amgen. Amgen Acquires Dark Blue Therapeutics, Bolstering … blue-therapeutics-bolstering-oncology-pipeline Amgen. Amgen Takes Action with the U …

… estimates. #6: Amgen The Skinny: Biotech Amgen (NASDAQ:AMGN) (AMGN, 2.9% yield) … medicines. Amgen is one of the most established biotechnology stocks, … further propel shares. Amgen More Than Doubled Rare … on Walmart (NASDAQ:WMT) and Costco (NASDAQ:COST) white- …

… as before. Continue Reading Post-Amgen Enablement: How the Federal … Court’s 2023 ruling in Amgen v. Sanofi, are placing … patent’s disclosure. Although Amgen arose in biotechnology, courts are now … broad functional claims. Assessing Amgen v. Sanofi and two …

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …

Collaboration with Amgen to advance a cancer target discovered using DISCO’s proprietary surfaceome mapping technology Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance …

… college, Josh worked for Amgen, a biotechnology company focused on developing medications …